Childhood Epilepsy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Childhood Epilepsy – Drugs In Development, 2024 report and make more profitable business decisions.
Childhood epilepsy is a neurological disorder characterized by recurring seizures in children. Seizures result from abnormal electrical activity in the brain, causing temporary disruptions in behavior, awareness, sensation, or consciousness. This condition can manifest in various forms, from brief staring spells to convulsions or loss of consciousness.
The causes of childhood epilepsy can vary, including genetic factors, brain injury, infections, developmental disorders, or unknown reasons in some cases. Diagnosis involves a comprehensive evaluation of medical history, physical exams, neurological tests, and sometimes imaging studies like electroencephalogram (EEG) to monitor brain activity.
The Childhood Epilepsy drugs in development market research report provide comprehensive information on the therapeutics under development for Childhood Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Childhood Epilepsy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Childhood Epilepsy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 74 molecules, with 71 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Childhood Epilepsy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Childhood Epilepsy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Childhood Epilepsy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
a:head Bio AGAdvantx Pharmaceuticals Inc
Advicenne SA
Anavex Life Sciences Corp
Aphios Corp
Astrogen Ltd
Azurity Pharmaceuticals Inc
Baergic Bio Inc
Bio-Pharm Solutions Co Ltd
BioNxt Solutions Inc.
Bloom Science Inc
Bright Minds Biosciences Inc
CAMP4 Therapeutics Corp
Celosia Therapeutics Pty Ltd
Cerecin Pte Ltd
Clinuvel Pharmaceuticals Ltd
CuroNZ Ltd
Cycle Pharmaceuticals Ltd
Deep Genomics Inc
Eisai Co Ltd
Encoded Therapeutics Inc
EpyGenix Therapeutics Inc
First Medical Center of Chinese PLA General Hospital
Genus Lifesciences Inc
Herophilus
IAMA Therapeutics Srl
Icahn School of Medicine at Mount Sinai
Jazz Pharmaceuticals Plc
JD Bioscience Inc
Johns Hopkins University
LifeSplice Pharma LLC
Longboard Pharmaceuticals Inc
Marinus Pharmaceuticals Inc
Mediphage Bioceuticals Inc
NeuCyte Inc
Neuroene Therapeutics LLC
Otsuka Pharmaceutical Co Ltd
Ovid Therapeutics Inc
Panaxia Pharmaceutical Industries Ltd
PannTheraPi
Praxis Precision Medicines Inc
Quiver Bioscience Inc
Regel Therapeutics Inc
Sentynl Therapeutics Inc
Shackelford Pharma Inc
Shanghai Pharmaceuticals Holding Co Ltd
SK Life Science Inc
Stoke Therapeutics Inc
StrideBio Inc
Sumitomo Pharma Co Ltd
Supernus Pharmaceuticals Inc
Taho Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Tevard Biosciences LLC
Theracule AS
UCB SA
Xenon Pharmaceuticals Inc
Xeris Biopharma Holdings Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Childhood Epilepsy reports